The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Open accessAbstract
BACKGROUND: Uveal melanoma is a disease that is distinct from cutaneous melanoma, with a low tumor mutational burden and a 1-year overall survival of approximately 50% in patients with metastatic uveal melanoma. Data showing a proven overall survival benefit with a systemic treatment are lacking. Tebentafusp is a bispecific protein consisting of an affinity-enhanced T-cell receptor fused to an anti-CD3 effector that can redirect T cells to target glycoprotein 100-positive cells. METHODS: In this open-label, phase 3 trial, we randomly assigned previously untreated HLA-A*02:01-positive patients with metastatic uveal melanoma in a 2:1 ratio to receive tebentafusp (tebentafusp group) or the investigator's choice of therapy with single-agent pembrolizumab, ipilimumab, or dacarbazine (control group), stratified according to the lactate dehydrogenase level. The primary end point was overall survival. RESULTS: A total of 378 patients were randomly assigned to either the tebentafusp group (252 patients) or the control group (126 patients). Overall survival at 1 year was 73% in the tebentafusp group and 59% in the control group (hazard ratio for death, 0.51; 95% confidence interval [CI], 0.37 to 0.71; P<0.001) in the intention-to-treat population. Progression-free survival was also significantly higher in the tebentafusp group than in the control group (31% vs. 19% at 6 months; hazard ratio for disease progression or death, 0.73; 95% CI, 0.58 to 0.94; P = 0.01). The most common treatment-related adverse events in the tebentafusp group were cytokine-mediated events (due to T-cell activation) and skin-related events (due to glycoprotein 100-positive melanocytes), including rash (83%), pyrexia (76%), and pruritus (69%). These adverse events decreased in incidence and severity after the first three or four doses and infrequently led to discontinuation of the trial treatment (2%). No treatment-related deaths were reported. CONCLUSIONS: Treatment with tebentafusp resulted in longer overall survival than the control therapy among previously untreated patients with metastatic uveal melanoma. (Funded by Immunocore; ClinicalTrials.gov number, NCT03070392; EudraCT number, 2015-003153-18.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, tebentafusp-tebn, a bispecific fusion protein consisting of a soluble TCR specific to gp100 (expressed by melanoma cells) linked to an anti-CD3 single-chain antibody fragment that targets T cells, has been approved for the treatment of metastatic uveal melanoma based on an OS benefit observed in a phase III trial199.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [199]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Tumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230
Wolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214
Self-citationDiscrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Checking the Cox model with cumulative sums of martingale-based residuals
LIN, D. Y., WEI, L. J., & YING, Z. (1993) · Biometrika · doi:10.1093/biomet/80.3.557 · Cited by 1,432
Very Long-Term Prognosis of Patients with Malignant Uveal Melanoma
Kujala, E., Mäkitie, T., & Kivelä, T. (2003) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.03-0538 · Cited by 1,046
Jager, M. J., Shields, C. L., Cebulla, C. M., Abdel‐Rahman, M. H., Grossniklaus, H. E., Stern, M., Carvajal, R. D., Belfort, R. N., Jia, R., Shields, J. A., et al. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0158-0 · Cited by 857
Self-citation
Cited by
Sorted by citations
Items 801–900 of 935
Krohn, J., Vinnem, L. I. H., Jansson, R. W., & Straume, O. (2025) · BMC Ophthalmology · doi:10.1186/s12886-025-04274-7
Toxizität der gerichteten Immuntherapie (CAR-T-Zellen und bispezifischen T-Zellaktivatoren)
Ochsenreither, S. (2025) · Springer Reference Medizin · doi:10.1007/978-3-662-46764-0_399-1
Self-citationWei, T., Cao, W., Zhang, Q., Wu, E. Q., Li, Q., & Ren, L. (2025) · Cancer Science · doi:10.1111/cas.70192
Pfister, S. K., Seehusen, F., Prisco, F., Rotta, G., Elsayed, A., Gilardoni, E., Thorhallsdottir, G., Pellegrino, C. E., Manz, M. G., Puca, E., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-25-0340
Swords, E., O’Reilly, E., Oladimeji, T., Carey, M., Tonelotto, V., & Kennedy, B. N. (2025) · Open Research Europe · doi:10.12688/openreseurope.20675.1
Kadefors, M., Nelson, A., Blomberg, E., Ståhlberg, A., Ny, L., & Bagge, R. O. (2025) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2025.101079
Surgical interventions improve survival in patients with metastatic uveal melanoma
Fingret, J. M., Sisley, K., Valluru, M. K., Rennie, I., Salvi, S. M., Allen, H., & Majeed, A. W. (2025) · Clinical Surgical Oncology · doi:10.1016/j.cson.2025.100102
Bayesian Prediction of Event Times Using Mixture Model for Blinded Randomized Controlled Trials
Fu, J., Zhao, D., Skanji, D., Liu, H., Tang, R. S., & Yuan, Y. (2025) · Statistics in Medicine · doi:10.1002/sim.70310
Sidhom, S. S., Hrabak, C., Shabbir, Z., Chang, S. J., Kazemeini, S., Akbar, S., Madappallil, J., Whitely, A., & Fraiser, K. (2025) · Research Square · doi:10.21203/rs.3.rs-7794706/v1
Mahumud, R. A., Shahjalal, M., Dahal, P. K., Mosharaf, M. P., Hoque, M. E., & Wawryk, O. (2024) · Figshare · doi:10.6084/m9.figshare.26241351
Huang, Y., Li, J., Li, M., & Aparasu, R. R. (2024) · Figshare · doi:10.6084/m9.figshare.26639016
Huang, Y., Li, J., Li, M., & Aparasu, R. R. (2024) · Figshare · doi:10.6084/m9.figshare.26639010
Huang, Y., Li, J., Li, M., & Aparasu, R. R. (2024) · Figshare · doi:10.6084/m9.figshare.26639007
Yang, B., Fan, Y., Liang, R., Wu, Y., & Gu, A. (2023) · Figshare · doi:10.6084/m9.figshare.22600366
Huang, Y., Li, J., Li, M., & Aparasu, R. R. (2024) · Figshare · doi:10.6084/m9.figshare.26639013
Mahumud, R. A., Shahjalal, M., Dahal, P. K., Mosharaf, M. P., Hoque, M. E., & Wawryk, O. (2024) · UWA Profiles and Research Repository (University of Western Australia) · doi:10.6084/m9.figshare.26241204
Herrspiegel, C., Plastino, F., Lardner, E., Seregard, S., Williams, P. A., André, H., & Stålhammar, G. (2023) · Figshare · doi:10.6084/m9.figshare.22621585
Ocular Melanoma: an Update on Surgical Approaches To Diagnosis, Characterization, and Therapy
Thuma, T. B. T., Razavi, P., Chaudhury, A., Garcia, A. P., Festok, M., Khan, M., Mahrous, A., Kovacs, K., Marr, B., Kiss, S., et al. (2025) · Current Surgery Reports · doi:10.1007/s40137-025-00483-7
Matet, A., Malaise, D., Rouïc, L. L.-L., & Cassoux, N. (2025) · EMC - Traité de médecine AKOS · doi:10.1016/s1634-6939(25)45202-8
Hard Truth About Surveillance for Uveal Melanoma
Francis, J. H. (2025) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.70041
Biologics in ocular oncology — Evolving paradigms and emerging horizons
Agrawal, G. A. (2026) · IP International Journal of Ocular Oncology and Oculoplasty · doi:10.18231/j.ijooo.80535.1767951108
Cai, Z., Huang, Y., Han, Y., Liu, Z., & Jiang, W. (2026) · Aging Research · doi:10.26599/agr.2026.9340064
Liang, Z., Guan, F., Wu, B., Chen, W., Tian, Y., Cai, W., & Li, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1736294
Circulating Tumor Cells in Uveal Melanoma: Multi-Marker Detection and Association With Disease State
de Bruyn, D. P., Bassil, F. L., Wu, M., Beasley, A. B., Vaarwater, J., Van, M. N., Kraan, J., Verdijk, R. M., Paridaens, D. A., van Rij, C. M., et al. (2026) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.67.1.55
Wang, G., & Zang, T. (2025) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm66473.2025.11356131
Kissinger, C. R., Miller, D., Li, Z., Ashraf, U. M., Hubbard, G. K., & Wilson, M. A. (2026) · Melanoma Research · doi:10.1097/cmr.0000000000001077
Maselli-Schoueri, J. H., & Saibil, S. D. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1767211
Yu, H., Wen, X., Cui, M. H., & Liu, S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1769251
Nanobiotechnology‐Based Approaches for Uveal Melanoma Treatment
Печникова, Н. А., Iliadis, I., Poimenidou, M., Patsidou, C., Zafeiriou-Chatziefraimidou, M., Almaliotis, D. D., Tsinopoulos, I., Zelepukin, I. V., & Yaremenko, A. V. (2026) · SmartMat · doi:10.1002/smm2.70065
Yeast surface display meets immunotherapy: unlocking the potential of T cells
Wang, J., Li, Y., Shi, J., Yao, Z., Yuan, P., Li, S., Wang, H., Chen, G. D., He, W., & Wu, D. (2026) · Cytotherapy · doi:10.1016/j.jcyt.2026.102102
Ni, J. R., Quirk, M., Chmielowski, B., & Padia, S. A. (2026) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-026-04373-y
Bispecifics: The future of therapeutic antibodies
Davis, J. H. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00093-5
Kasteleiner, P., Grözinger, G., Schmehl, J., Flatz, L., & Forschner, A. (2026) · International Journal of Cancer · doi:10.1002/ijc.70418
Dalvin, L. A., Burr, S. D., Ong, H., & Armitage, J. A. (2026) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2026.2642974
Fiorentzis, M., Bechrakis, N. E., & Kiefer, T. (2026) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-2680-5849
ImmTACs overcome cytotoxic T cell suppression
Huynh, L., Aljohani, A., Alsubaiti, A., Grant, T., Chapman, A., Phillips, G., Chamberlain, J. M. G., Hayward-Wills, A., Jungwirth, U., Salio, M., et al. (2025) · Immunotherapy Advances · doi:10.1093/immadv/ltag020
Self-citationZhao, Y., Hou, C., Xiao, L., Liu, L., & Yan, N. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27073027
Matet, A., Malaise, D., Rouïc, L. L.-L., & Cassoux, N. (2026) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(26)51685-4
Tissue and systemic tumor antigen-specific responses at different stages of uveal melanoma
Lucibello, F. (2022) · theses.fr (ABES) · doi:10.70675/a435c499zb443z4e87z9bf7za082285fa483
Scharl, M. M., Truscello, L., Morsy, Y., Hubeli, B., Bürki, M., Ferreira, D. M., Esposito, M., Ramelyte, E., Mangana, J., Gomez, J. P., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9278584/v1
Self-citationEtude des mécanismes de contrôle des cellules tumorales par les cellules Natural Killer
Fenis, A. (2024) · theses.fr (ABES) · doi:10.70675/747c59caz7a79z4064z989cz9dd2bc8bd27e
Vlašić, D., Zagorec, M. K., Jakovčević, A., Gaćina, D. L., Ćorić, M., & Jukić, T. (2026) · Cancers · doi:10.3390/cancers18081211
Larue, M., Ferment, B., Allain, V., Fadlallah, J., Hervier, B., Arnulf, B., & Talbot, A. (2026) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2026.03.441
Identification of Combinatorial Targets for Anticancer Drug Discovery
Huang, M., & Geng, M. (2026) · 中国科学基金 · doi:10.3724/bnsfc-2025-0011
Howell, W. M. (2026) · International Journal of Immunogenetics · doi:10.1111/iji.70052
Levesque, M. P., Hermes, V., Esposito, M., Brooks, K. M., Gueguen, P., Hofer, M., Ghosh, A., Staeger, R., Shukla, P., Gomez, J. M., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9503349/v1
Self-citationKnapen, D. G., van Winkel, C. A. J., Grevelink, T., van Sluis, J., Hooge, M. N. L., Brouwers, A. H., van der Vegt, M., Bhattacharya, A., Wong, T. L. H., Brailey, P. M., et al. (2026) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-25-0610
Koch, E. A. T., Schielein, L., Reitmajer, M., Glaser, A.-C., Drexler, K., Franklin, C., Forschner, A., Berking, C., Hassel, J. C., Heppt, M. V., et al. (2026) · The Oncologist · doi:10.1093/oncolo/oyag152
Self-citationFiorentzis, M., Bechrakis, N. E., & Kiefer, T. (2026) · Augenheilkunde up2date · doi:10.1055/a-2833-0028
Neue Therapieansätze beim Melanom
Urban, V., Schreieder, L., Drexler, K., & Haferkamp, S. (2026) · Im Focus Onkologie · doi:10.1007/s15015-026-4624-8
Shakha, Chawla, B. V., & Sen, S. (2026) · Advances in Ophthalmology and Optometry · doi:10.1016/j.yaoo.2026.04.003
Chen, Q., Zhou, J., Zhou, H., Wang, H., & Li, J. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1811719
Spatial Omics Revisits Cancer Immunity and Reshapes Immunotherapy
Chu, H., Shi, Y., Tian, Z., Ma, J. Y., Bian, X. W., & ZHU, B. (2026) · Fundamental Research · doi:10.1016/j.fmre.2026.04.033
Escape From Synthetic T Cell Activator Tebentafusp by Genomic HLA Loss: A Case Report
Kalkavan, H., Heinold, A., Liu, S., Borse, G. M., Heinemann, F. M., Dertnig, T., Hense, J., Ingenwerth, M., Cheung, F.-Y., Antonopoulou, G., et al. (2026) · HLA · doi:10.1111/tan.70764
Петрова, К. Д. (2026) · Международный студенческий научный вестник (International Student Scientific Herald) · doi:10.17513/msnv.22150
Prognostic Biomarkers of Survival in Ocular Melanoma
Bobrek, C. N., Sarvepalli, S. M., Bailey, B., & Hadziahmetovic, M. (2026) · Ophthalmic Epidemiology · doi:10.1080/09286586.2026.2678907
Narayana, R. V. L., Lanier, A. L., Wajapeyee, N., & Gupta, R. (2026) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2026.03.036
From T cell engagers to next-generation immune cell engagers for cancer immunotherapy
Yang, Z., & Fu, Y. (2026) · Antibody Therapeutics · doi:10.1093/abt/tbag030
Kalondero, E. M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1845119
Zahrieh, D., Wang, X., Markovic, S. N., & Suman, V. J. (2026) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2026.101653
Fast, E., Dhar, M., Gulati, G. S., Ku, M., & Chen, B. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.08.730987
Card, K. R., Haq, R., Mignano, J. E., & Desai, S. J. (2026) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.70091
Mani, R., Enzinger, L., Thommes, C., Devlitsarov, D., Rokohl, A. C., Deisl, C., Heindl, L. M., & Pruszak, J. (2026) · Cancers · doi:10.3390/cancers18121891
Generative design of antigen-specific T-cell receptor sequences with a conditional diffusion modelPreprint
Zhang, Y., Liang, W., 许舒婷, Witney, M. J., Su, X., Andrews, M. C., Rossjohn, J., Purcell, A. W., Wang, F., & Song, J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.10.730756
Monaca, F., Woodford, R., Joshi, K., Thistlethwaite, F. C., Lim, K. H. J., & Gomez-Randulfe, I. (2026) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359261457552
GWAS meta-analysis provides new insights into uveal melanoma risk
D'Mellow, M. G., Wang, H., Palmer, J. M., Hemminki, K., Cebulla, C. M., Beasley, A. B., Bechrakis, N. E., Pritchard, A. L., Wadt, K. W., Johansson, P. A., et al. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03499-7
Caglevic, C., Contreras-Torrez, M. A., Reyes-Cosmelli, F., Maturana, R. U., Mahave, M., Caire, N., Villanueva-Olivares, L., Cid, F., Lladser, Á., & Sapunar, J. (2026) · Antibodies · doi:10.3390/antib15030049
Cai, H., Huang, Z., Wang, B., Ming, W., Tian, M., & Zheng, H. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1826626
Turner, J. A., D’Antonio, M. A., Montane, H. N., MacBeth, M. L., Katsnelson, E., Robinson, W. A., Tobin, R. P., Couts, K. L., Markovic, S. N., & Torres, R. M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1829486
Łuniewska, W., Jabłoński, M., Kobaka, L., Chołast, J., Kacer, J., Kacer, J., Niepokój, J., Jurga, K., & Modrzyk, M. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5917
Wilson, R. J., Ramlogan‐Steel, C. A., Deasy, W. J., Greenstein, S., Layton, C. J., & Steel, J. C. (2026) · BioDrugs · doi:10.1007/s40259-026-00794-w
Immunotherapy for Melanoma: A Concise Clinical Review for Australasian Practice
Stacy, A., Wynn, L., & Seebacher, N. A. (2026) · Australasian Journal of Dermatology · doi:10.1111/ajd.70158
Habibzadeh, P., Kulkarni, A., Hurd, D. E., Rose, A., Bednarz, D., Najjar, Y. G., Kirkwood, J. M., Karunamurthy, A. D., & Davar, D. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1864115
Self-citationNot Always ICANS: Interpreting Neurotoxicity With Tarlatamab in SCLC
Hennawy, M., Harrison, R. A., & Ho, C. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2026.103723
Neoadjuvant and adjuvant therapy in uveal melanoma: toward systemic control of a systemic disease
Foteinou, D., Theocharopoulos, C., Varvoglis, D. N., Ziogas, I. A., Petrou, P., Patel, S. P., Oliver, S. C. N., Gogas, H., & Ziogas, D. C. (2026) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2026.103181
A Phase II Trial of Defactinib Combined with Avutometinib in Patients with Metastatic Uveal Melanoma
Seedor, R. S., Terai, M., Koshkin, S., Aplin, A. E., Orloff, M. M., Sharpe-Mills, E., Naccarato, M., Mills, A., Molinolo, A., Gutkind, J. S., et al. (2026) · Cancers · doi:10.3390/cancers18142232
Self-citationHattersley, J., Aughton, K., Coupland, S. E., & Kalirai, H. (2026) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2026.101493
Zhu, T., Li, Y., Tang, J., Lin, H., Gu, X., Ge, S., Ye, L., Wu, P., Fan, X., Zhuang, A., et al. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.07.027
Sweis, R. F., Melero, I., Davar, D., Garralda, E., Hamid, O., Chen, H. A., Evans, T. R. J., Moore, K. N., Sacco, J. J., Thistlethwaite, F. C., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-014638
Self-citationMa, Y.-J., Zhang, Z., Kang, J., Che, X.-H., Tian, J.-Y., Cai, Y.-Y., Shen, S., Zhao, D., & Zhu, L. (2026) · Biomaterials Science · doi:10.1039/d6bm00886k
Modeling rare melanoma subtypes: mechanisms, microenvironments and translational opportunities
Meng, Q., Yan, F., You, C., Xu, R., Jing, T., Ni, D., Hou, C., Xu, D., Liu, S., Guo, F., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1832600
Integrating T cell signaling and metabolism to enhance T cell engager responses in solid tumors
Scaglione, M., Engavale, M. B., Chun, M. G. H., Sawant, D. V., Lu, D., & LaGory, E. L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1887842
Does the ERBB/EGF Signaling Network Serve as a Nexus for Oncogenic Signals in Uveal Melanoma?
Raeesian, N., & Riese, D. J. (2026) · Biomolecules · doi:10.3390/biom16081079
Huang, T., Wang, R., Zhang, D., Wu, S., Wang, Y., Wang, J., Ren, Z., Wang, S., Li, L., Zhou, Y., et al. (2026) · doi:10.65215/ltspreprints.2026.07.28.000297
Huang, T., Wang, R., Zhang, D., Wu, S., Wang, Y., Wang, Y., Ren, Z., Wang, S., Li, L., Zhou, Y., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.26.740839
Guo, Z., Zhu, R., Wei, C., Wang, B., Lv, Y., Tan, J., Xiu, L., & Li, J. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103525
Meyer, M., Peters, S., Ahn, M., Beuchat, I., Borghaei, H., Byers, L. A., Cappuzzo, F., Choudhury, N. J., Bono, J. S. D., Felip, E., et al. (2026) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2026.103201
Awni, B. M., Zanetta, G. K., Olivato, G. B., Serur, I. P., de Almeida, V. D., Pinheiro, M. A. L., & Munhoz, R. R. (2026) · Brazilian Journal of Oncology · doi:10.1055/s-0046-1824769
Systemic surveillance for uveal melanoma: Approach to optimization
Zabor, E. C., Yeşiltaş, Y. S., & Singh, A. D. (2026) · PLoS ONE · doi:10.1371/journal.pone.0355405
Tumor-tropic E. coli engineered as living T and NK cell engagersPreprint
Yang, S., Bader, A. C., Sendker, S., Hu, A., Chen, D. C., Nath, H., Chen, A., Bobilev, E., Sheffer, M., Hui, V. W., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.18.745642
Teschner, A. C., Gonçalves, M., Meyer, M., Zörnig, I., Jäger, D., & Momburg, F. (2026) · Cells · doi:10.3390/cells15171545
Dai, H., Zhang, X. M., Zhang, J. C., Deng, X. T., Liu, Q., Ali, M. H., Yin, F. Z., & Yin, W. (2026) · Advanced Science · doi:10.1002/advs.77458
A review on toxicities of T-cell engager-based therapies in solid tumors
Bastien, E., Vacheret, C., Sanchez, R., Lucibello, F., Girard, N., & Romano, E. (2026) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359261467651
Potential of Nanoparticle‐Based Phototherapies for Future Treatment of Uveal Melanoma
Lambert, É., Nguyen, C., Dunn, S. E., Gary‐Bobo, M., Lacombe, J., Moser, J. C., Zenhausern, F., Durand, J., & Cunin, F. (2026) · Advanced Science · doi:10.1002/advs.77396
Hofmann, M., Unverdorben, F., Pszolla, M. G., Aschmoneit, N., Hutt, M., Manz, T., Schuster, H., Hukelmann, J. L., Acs, A., Tenkerian, C., et al. (2026) · mAbs · doi:10.1080/19420862.2026.2722707
Fakih, M., Doi, T., Tolcher, A. W., Hong, D. S., Tie, J., Messersmith, W. A., Koyama, T., Rosen, L. S., Borlido, J., Damore, M. A., et al. (2026) · Cancer Research Communications · doi:10.1158/2767-9764.crc-26-0101
Key barriers in utilizing advanced T-cell engager strategies on solid tumors
Ku, B. M., Lim, S.-W., Uhm, J., Park, B.-B., & Ahn, M.-J. (2026) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2026.2730177
Dumbrava, E. E. I., Oh, D., Ryu, M., Calvo, E., Garralda, E., Chung, W., Bai, L., Lamito, K. R., Yildirim, O., Masciari, S., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-014309
Anastasova, R., Fiorentzis, M., Yousefiboroujeni, A., Gallo, G. P., Cadossi, M., Dalbah, S., Seitz, B., Bechrakis, N. E., & Tsimpaki, T. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1860536
Metadata
- Authors
- Nathan, P., Hassel, J. C., Rutkowski, P., Baurain, J.-F., Butler, M. O., Schlaak, M., Sullivan, R. J., Ochsenreither, S., Dummer, R., Kirkwood, J. M., Joshua, A. M., Sacco, J. J., Shoushtari, A. N., Orloff, M., Piulats, J. M., Milhem, M., Salama, A. K. S., Curti, B., Demidov, L., Gastaud, L., Mauch, C., Yushak, M., Carvajal, R. D., Hamid, O., Abdullah, S. E., Holland, C., Goodall, H., & Piperno-Neumann, S.
- Affiliations
- University of Liverpool (GB)
- From Mount Vernon Cancer Centre, Northwood (P.N.), the Clatterbridge Cancer Centre NHS Foundation Trust, Wirral (J.J.S.), the University of Liverpool, Liverpool (J.J.S.), and Immunocore, Abingdon (S.E.A., C.H., H.G.) — all in the United Kingdom; the Department of Dermatology and the National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg (J.C.H.), the Department of Dermatology and Allergy, University Hospital, Ludwig Maximilian University of Munich, Munich (M.S.), the Department of Hematology and Oncology, Charité–Comprehensive Cancer Center (S.O.), Berlin, and the Department of Dermatology and the Center for Integrated Oncology, University Hospital Cologne, Cologne (C.M.) — all in Germany; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland (P.R.); Institut Roi Albert II des Cliniques Universitaires Saint-Luc and Université Catholique de Louvain, Brussels (J.-F.B.); Princess Margaret Cancer Centre, Toronto (M.O.B.); Massachusetts General Hospital Cancer Ce...
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Nathan, Paul
- Hassel, Jessica C.
- Rutkowski, Piotr
- Butler, Marcus O.
- Schlaak, Max
- Sullivan, Ryan J.
- Ochsenreither, Sebastian
- Dummer, Reinhard
- Kirkwood, John M.
- Joshua, Anthony M.
- Sacco, Joseph J.
- Shoushtari, Alexander N.
- Orloff, Marlana
- Piulats, Josep M.
- Milhem, Mohammed
- Salama, April K.S.
- Curti, Brendan
- Mauch, Cornelia
- Yushak, Melinda
- Carvajal, Richard D.
- Hamid, Omid
- Abdullah, Shaad E.
- Piperno-Neumann, Sophie
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-09-23
- Volume
- 385
- Issue
- 13
- Pages
- 1196-1206
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3200574709
- Cited by
- 924
- References
- 28
- Citations by year
- 2026: 158 · 2025: 181 · 2024: 216 · 2023: 205 · 2022: 148 · 2021: 15
- FWCI
- 131.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- metastatic uveal melanoma, bispecific T-cell engagers, anti-CD3 antibody, pembrolizumab, ipilimumab, dacarbazine, overall survival, progression-free survival, HLA-A*0201, cytokine release syndrome, treatment-related adverse events, treatment-naive patients
- MeSH terms
- Ipilimumab, Cytokine Release Syndrome, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Dacarbazine, Exanthema, Female, Humans, Male, Melanoma, Middle Aged, Recombinant Fusion Proteins, Uveal Neoplasms, Survival Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
